More Outperformance Ahead For These 2 “Class of 2018” Biotech Stocks?
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
An intranasal vaccine, an mRNA vaccine, and a T-cell activation vaccine: the three biotech companies discussed in today’s article are approaching the virus that causes…
When it comes to the biotech stock that’s the focus of today’s article, which plummeted in mid-October when the company abruptly pulled the plug on…
October has seen the FDA approve the first drug for COVID-19 (remdesivir), the first treatment for Ebola virus (Regeneron Pharmaceuticals’ Inmazeb), and the first drug…
The biotech stock highlighted in today’s article is already up 173% so far this year, and now the author advises that “a historically bullish signal…
The biotech company highlighted in today’s article, specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, is one that…
“Call it what you will, but I think traders who’ve dug into the biotech space initially came for the COVID, then figured out there’s far…
“We have a $5 billion market cap now. The next stage is for us to get to $20 billion,” declares the chief executive of the…
The clinical-stage biotech highlighted in today’s article – operating in the hot immuno-oncology sector – has both long-term and short-term bull cases to be made…
“This is a market that favors stock picking over market timing and macro analysis,” advises the author of today’s article, who argues that “The business…